Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

Shazad Mushtaq, Marina Warner, Alan P Johnson, David M Livermore

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.
Original languageEnglish
Pages (from-to)617-20
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Issue number3
Publication statusPublished - Sep 2004


  • Anti-Bacterial Agents
  • Culture Media
  • Drug Resistance, Multiple, Bacterial
  • Glycopeptides
  • Microbial Sensitivity Tests
  • Staphylococcus
  • Streptococcus
  • Teicoplanin

Cite this